Key Takeaways:
- Exceptionally strong recovery: July funding skyrocketed over 23 times June’s level, showing renewed investor confidence.
- Late‑stage dominance: Unlike June’s early‑stage focus, July was overwhelmingly driven by late‑stage capital (~92 per cent of total funding).
- Mega deals fueled growth: Meril’s $200 million round kindled the month’s momentum, dwarfed by smaller midsize rounds, indicating a return of high‑value investment rounds.
In July 2025, India’s pharma and healthcare ecosystem saw a dramatic surge in investment activity. Total funding reached $294 million across 18 rounds, representing a 2356.8 per cent increase from June 2025’s $12 million and a 574.1 per cent rise compared to July 2024. July 2025 also marked a 20 per cent uptick from $245.8 million raised in May 2025.
Late-stage funding led the mix, capturing 92.3 per cent of total capital, while seed-stage funding made up 4.2 per cent, and early-stage rounds accounted for 3.5 per cent of investments.
The most notable funding round in July was secured by Meri, which raised $200 million. This was followed by MedGenome at $47.5 million, Truemeds at $20 million, SAI Parenterals at $5.8 million, Pristyn Care at $4 million, Luma Fertility at $4 million, and Biopeak at $3.5 million.
Peak XV Partners participated in three funding rounds for Truemeds, Pristyn Care, and Luma Fertility. Samarah Capital backed one funding round for SAI Parenterals, and Gujarat Venture Finance backed one funding round for Genexis Biotech.
Key Takeaways:
Exceptionally strong recovery: July funding skyrocketed over 23 times June’s level, showing renewed investor confidence.
Late‑stage dominance: Unlike June’s early‑stage focus, July was overwhelmingly driven by late‑stage capital (~92 per cent of total funding).
Mega deals fueled growth: Meril’s $200 million round kindled the month’s momentum, dwarfed by smaller midsize rounds, indicating a return of high‑value investment rounds.
In July 2025, India’s pharma and healthcare ecosystem saw a dramatic surge in investment activity. Total funding reached $294 million across 18 rounds, representing a 2356.8 per cent increase from June 2025’s $12 million and a 574.1 per cent rise compared to July 2024. July 2025 also marked a 20 per cent uptick from $245.8 million raised in May 2025.
Late-stage funding led the mix, capturing 92.3 per cent of total capital, while seed-stage funding made up 4.2 per cent, and early-stage rounds accounted for 3.5 per cent of investments.
The most notable funding round in July was secured by Meri, which raised $200 million. This was followed by MedGenome at $47.5 million, Truemeds at $20 million, SAI Parenterals at $5.8 million, Pristyn Care at $4 million, Luma Fertility at $4 million, and Biopeak at $3.5 million.
Peak XV Partners participated in three funding rounds for Truemeds, Pristyn Care, and Luma Fertility. Samarah Capital backed one funding round for SAI Parenterals, and Gujarat Venture Finance backed one funding round for Genexis Biotech.